ProQR Therapeutics N.V.
PRQR
$1.76
-$0.06-3.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.38M | -12.87M | -13.82M | -10.61M | -9.92M |
| Total Depreciation and Amortization | 790.40K | 784.50K | 766.10K | 713.50K | 715.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.54M | 1.37M | 1.45M | 341.00K | -182.30K |
| Change in Net Operating Assets | -7.50M | -3.59M | -1.34M | -7.07M | -578.80K |
| Cash from Operations | -15.55M | -14.30M | -12.94M | -16.63M | -9.96M |
| Capital Expenditure | -612.30K | -197.60K | -114.60K | -235.70K | -141.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -2.83M |
| Cash from Investing | -612.30K | -197.60K | -114.60K | -235.70K | -2.97M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -601.00K | -444.00K | -293.00K | -567.00K | -253.00K |
| Issuance of Common Stock | 2.00K | -- | -- | 67.00K | 71.68M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -697.30K | -519.10K | -332.50K | -526.20K | 76.14M |
| Foreign Exchange rate Adjustments | 14.00K | -39.80K | -969.20K | -496.70K | 760.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.84M | -15.06M | -14.36M | -17.88M | 63.97M |